Nathan Dau

Executive Director
2017 - 2024
Focused on making growth equity and private equity investments in commercial stage healthcare companies. Target sectors include pharma services, medtech, health tech, dx/tools and synthetic biology. Lead or co-lead investor on all deals. Notable investments include Surgical Specialties (sold to GTCR), Preventice (sold to Boston Scientific), PatientPop (merger with Kareo to form Tebra), Seran Biosciences, Scientia, Histowiz, InBrace, Aerobiotix, Amyris, and Sera Prognostics (IPO).

2015 - 2017

Senior Associate
2015 - 2017
Growth equity investments in enterprise software companies.

2012 - 2015

Associate
2012 - 2015
Advised on over $28 billion of M&A transactions. Deals included sell-side and buy-side M&A and leveraged buyouts across multiple sectors including energy, industrials, homebuilding, media, and technology. Led the preparation of financial models and valuation analyses. Advised clients on M&A opportunities, capital allocation strategy, and PE investor exit scenarios.

2006 - 2010

Associate
2006 - 2010
Represented targets and acquirers in connection with seven M&A transactions with an aggregate deal value of over $2.2 billion. Advised issuers in connection with three IPOs, raising over $730 million of aggregate capital, and advised clients on debt offerings and private placements, raising over $2.5 billion of proceeds.

Head of Private Investments